The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLPE.L Regulatory News (SLPE)

  • There is currently no data for SLPE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Estimated NAV at 30 September 2020

14 Oct 2020 07:00

RNS Number : 9329B
Standard Life Private Eqty Trst PLC
14 October 2020
 

Standard Life Private Equity Trust plc

Legal Entity Identifier (LEI): 2138004MK7VPTZ99EV13

 

14 October 2020

· Standard Life Private Equity Trust plc ("SLPET" or "the Company") announces its estimated net asset value ("NAV") at 30 September 2020

· Estimated NAV at 30 September 2020 was 466.5 pence per share (estimated NAV at 31 August 2020 was 459.9 pence per share)

· SLPET paid £19.7 million of drawdowns and received £14.2 million of distributions during the month of September

· Outstanding commitments of £471.4 million at 30 September 2020

SLPET's valuation policy for private equity funds and co-investments is based on the latest valuations reported by the managers of the funds and co-investments in which the Company has interests. In the case of SLPET's valuation at 30 September 2020, excluding new investments, 100.0% by value of the portfolio valuations were dated 30 June 2020.

 

Estimated NAV

At 30 September 2020, SLPET's estimated NAV was 466.5 pence per share (estimated net assets £717.2 million), representing a 1.4% per share increase from the estimated NAV at 31 August 2020 of 459.9 pence per share (estimated net assets £707.1 million). The 6.6 pence increase in NAV per share reflected gains arising primarily from a 1.5% appreciation in the euro versus sterling during September.

 

Drawdowns and distributions

SLPET paid £19.7 million of drawdowns and received £14.2 million of distributions during the month of September. The distributions received generated realised gains and income of £7.2 million.

 

Secondary activity

On 30 September 2020, the Company acquired through secondary purchase, an original commitment of €6.4 million to Vitruvian III. The Company assumed outstanding commitments of €2.6 million on acquisition.

 

Commitments

A new commitment of €25 million was made to Nordic Capital X in September. The Company had £471.4 million of outstanding commitments at 30 September 2020. The Manager believes that around £67.1 million of the Company's existing outstanding commitments are unlikely to be drawn.

 

Balance sheet and credit facility

The Company had cash and cash equivalents of £33.2 million at 30 September 2020. In addition, it is due £15.3 million of deferred consideration during the year from investments sold in 2019. It also has an undrawn £200 million syndicated revolving credit facility, provided by Citi, Societe Generale and State Street Bank International, that expires in December 2024.

 

Update on COVID-19

The Manager continues to be mindful of the impact of COVID-19 and maintains regular communication with the private equity managers of the Company's investments.

The latest update from the Manager, which provides responses to frequently asked questions in relation to COVID-19, is available within the Latest News section of the Company website; www.slpet.co.uk.

 

Future announcements

The Company is expecting to announce its estimated NAV at 31 October 2020 on 13 November 2020. 

Additional detail about SLPET's NAV and investment diversification can be found on SLPET's website. Neither the contents of the Company's website nor the contents of any website accessible from hyperlinks on the Company's website is incorporated into, or forms part of, this announcement.

 

For further information please contact Alan Gauld at SL Capital Partners LLP (0131 528 4424)

Note:-

Standard Life Private Equity Trust plc is an investment company managed by SL Capital Partners LLP, the ordinary shares of which are admitted to listing by the UK Listing Authority and to trading on the Stock Exchange and which seeks to conduct its affairs so as to qualify as an investment trust under sections 1158-1165 of the Corporation Tax Act 2010. The Board of Standard Life Private Equity Trust plc is independent of Standard Life Aberdeen plc and Phoenix Group Holdings.

Valuation Methodology

Unquoted investments are stated at the directors' estimate of fair value and follow the recommendations of EVCA and BVCA. The estimate of fair value is normally the latest valuation placed on a fund or co-investment by its manager at the balance sheet date. The valuation policies used by the manager in undertaking that valuation will generally be in line with the joint publication from EVCA and BVCA, 'International Private Equity and Venture Capital Valuation guidelines'. Where formal valuations are not completed at the balance sheet date the last available valuation from the fund manager or co-investment lead is adjusted for any subsequent cashflows occurring between the valuation date and the balance sheet date. The Company's Manager may further adjust such valuations to reflect any changes in circumstances from the last manager's formal valuation date to arrive at the estimate of fair value, for example, where sales proceeds are available. Quoted investments are valued based on quoted prices as of the last day of the relevant period.

The Company intends to release regular estimated NAV updates around ten business days after each month end, while continuing to issue quarterly updates. A breakdown of SLPET's portfolio can be obtained in the latest monthly factsheet, which is published on SLPET's website at:

www.slpet.co.uk

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NAVKKNBPCBDKFKD
Date   Source Headline
4th Apr 202212:06 pmRNSChange of Name
22nd Mar 20222:14 pmRNSResult of AGM
21st Mar 202211:26 amRNSDirector Declaration
14th Mar 20225:30 pmRNSFTSE Russell Indices
14th Mar 20227:00 amRNSEstimated NAV at 28 February 2022
9th Mar 20222:07 pmRNSFirst Interim Dividend
24th Feb 20227:00 amRNSEdison review on Standard Life Private Equity Trst
14th Feb 20227:00 amRNSEstimated NAV at 31 January 2022
4th Feb 20223:24 pmRNSAnnual Report
1st Feb 202212:45 pmRNSDirector/PDMR Shareholding
27th Jan 20227:05 amRNSEstimated NAV at 31 December 2021
27th Jan 20227:00 amRNSAnnual Financial Report
6th Jan 20229:04 amRNSQuarterly disclosure
15th Dec 20217:00 amRNSEstimated NAV as at 30 November 2021
14th Dec 20213:48 pmRNSFourth Interim Dividend
6th Dec 20217:00 amRNSEdison review on Standard Life Private Equity Trst
12th Nov 20217:00 amRNSEstimated NAV at 31 October 2021
2nd Nov 20214:25 pmRNSDirector/PDMR Shareholding
14th Oct 20217:00 amRNSEstimated NAV at 30 September 2021
4th Oct 20214:15 pmRNSQuarterly disclosure
29th Sep 20217:02 amRNSEstimated NAV at 31 August 2021
29th Sep 20217:00 amRNSQuarterly Investment Update at 30 June 2021
17th Sep 20211:10 pmRNSUpdate research from QuotedData
7th Sep 20217:00 amRNSThird Interim Dividend
1st Sep 20217:00 amRNSDirectorate Change
16th Aug 202110:19 amRNSDirector/PDMR Shareholding
13th Aug 20217:00 amRNSEstimated NAV at 31 July 2021
10th Aug 20214:41 pmRNSSecond Price Monitoring Extn
10th Aug 20214:35 pmRNSPrice Monitoring Extension
5th Aug 20213:32 pmRNSDirector/PDMR Shareholding
19th Jul 202111:58 amRNSEdison issues review on Standard Life Private
14th Jul 20219:05 amRNSDirector Declaration
14th Jul 20217:00 amRNSEstimated NAV at 30 June 2021
9th Jul 20213:29 pmRNSDoc re. Half yearly report
2nd Jul 20214:35 pmRNSQuarterly disclosure
29th Jun 20217:05 amRNSEstimated NAV at 31 May 2021
29th Jun 20217:00 amRNSHalf-year Report
14th Jun 20212:48 pmRNSSecond Interim Dividend
17th May 20217:00 amRNSEstimated NAV at 30 April 2021
12th May 20214:06 pmRNSDirector/PDMR Shareholding
27th Apr 202112:21 pmRNSDirector/PDMR Shareholding
22nd Apr 20217:05 amRNSEstimated NAV at 31 March 2021
22nd Apr 20217:00 amRNSQuarterly Investment Update at 31 December 2020
9th Apr 202111:58 amRNSHolding(s) in Company
6th Apr 20214:11 pmRNSQuarterly disclosure
23rd Mar 20211:50 pmRNSResult of AGM
12th Mar 20217:00 amRNSEstimated NAV as at 28 February 2021
8th Mar 20217:00 amRNSFirst Interim Dividend
25th Feb 20217:00 amRNSEdison review on Standard Life Private Eqty Trust
12th Feb 202110:22 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.